Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 86,038Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 9Basaglar

02 10Lantus

03 2Soliqua/iGlarLixi

04 1Soliqua/iGlarLixi

05 9Toujeo

PharmaCompass

01

Brand Name : Lantus

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine

Main Therapeutic Indication : Diabetes

Currency : USD

2014 Revenue in Millions : 11.00%

2013 Revenue in Millions :

Growth (%) :

Sanofi Company Banner

02

Brand Name : Toujeo

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine

Main Therapeutic Indication : Diabetes

Currency : USD

2019 Revenue in Millions : 962

2018 Revenue in Millions : 916

Growth (%) : 5

Sanofi Company Banner

03

Brand Name : Lantus

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine

Main Therapeutic Indication : Diabetes

Currency : USD

2019 Revenue in Millions : 3,283

2018 Revenue in Millions : 3,886

Growth (%) : -16

Sanofi Company Banner

04

Brand Name : Soliqua/iGlarLixi

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 195

2019 Revenue in Millions : 148

Growth (%) : 32

Sanofi Company Banner

05

Brand Name : Toujeo

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 1,129

2019 Revenue in Millions : 1,068

Growth (%) : 6

Sanofi Company Banner

06

Brand Name : Lantus

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 3,219

2019 Revenue in Millions : 3,643

Growth (%) : -12

Sanofi Company Banner

07

Brand Name : Soliqua/iGlarLixi

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 215

2020 Revenue in Millions : 175

Growth (%) : 21

Sanofi Company Banner

08

Brand Name : Toujeo

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 1,067

2020 Revenue in Millions : 1,017

Growth (%) : 4

Sanofi Company Banner

09

Brand Name : Lantus

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 2,746

2020 Revenue in Millions : 2,900

Growth (%) : -6

Sanofi Company Banner

10

Brand Name : Toujeo

arrow
2024 ACI Convention
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Glargine

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 1,225

2021 Revenue in Millions : 1,067

Growth (%) : 15

Sanofi Company Banner